

---

**Product Data Sheet**

---

Product Name: Risuteganib

Cat. No.: GC37541

**Chemical Properties**

Cas. No. 1307293-62-4

Formula  $C_{22}H_{39}N_9O_{11}S$  M.Wt 637.66

Solubility Soluble in DMSO Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure **Background**

Risuteganib is an anti-integrin peptide and a derivative of RGD peptide.<sup>1</sup> Risuteganib (400 μM) protects against hydroquinone-induced necrosis and apoptosis, as well as inhibits hydroquinone-induced production of reactive oxygen species (ROS), in human retinal pigment epithelial (RPE) cells.<sup>2</sup> It decreases the expression of *BAX*, *VEGFA*, and *ITB1* in human age-related macular degeneration (AMD) cybrid cell lines when used at a concentration of 20 mg/ml.<sup>3</sup> Risuteganib arrests aberrant blood vessel growth mediated by  $\alpha V\beta 3$ ,  $\alpha V\beta 5$ , and  $\alpha 5\beta 1$  integrins *in vivo*.<sup>1</sup>

1. Kaiser, P., Boyer, D.D., Campochiaro, P.A., et al. Integrin peptide therapy: The first wet AMD experience. *Invest. Ophthalmol. Vis. Sci.* 54(15):2177(2013)  
2. Yang, P., Shao, Z., Besley, N.A., et al. Risuteganib protects against hydroquinone-induced injury in human RPE cells. *Invest. Ophthalmol. Vis. Sci.* 61(10):35(2020)  
3. Differential effects of risuteganib and bevacizumab on AMD cybrid cells. *Exp. Eye Res.* 203:108287(2021)

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---